Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely

Journal of Hepatology

Volumn 58, Issue 4, 2013, Pages 676-683

  Chevaliez, Stéphane ^a,b   Hézode, Christophe ^b,c   Bahrami, Stéphane ^a   Grare, Marion ^a   Pawlotsky, Jean Michel ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b INSERM U955   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

HBs antigen level; Hepatitis B virus; Nucleoside nucleotide analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; KINETICS; LIMIT OF QUANTITATION; LONG TERM CARE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; TREATMENT DURATION; VIRUS DETECTION; VIRUS REPLICATION; VIRUS STRAIN;

ADENINE; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KINETICS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; ORGANOPHOSPHONATES;

EID: 84880939335     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.11.039     Document Type: Article

References (36)

1. H.L. Chan, V.W. Wong, A.M. Chim, H.Y. Chan, G.L. Wong, and J.J. Sung Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B Aliment Pharmacol Ther 32 2010 1323 1331
2. T. Nguyen, A.J. Thompson, S. Bowden, C. Croagh, S. Bell, and P.V. Desmond Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia J Hepatol 52 2010 508 513
3. C. Seeger, and W.S. Mason Hepatitis B virus biology Microbiol Mol Biol Rev 64 2000 51 68 (Pubitemid 30143840)
4. A.J. Thompson, T. Nguyen, D. Iser, A. Ayres, K. Jackson, and M. Littlejohn Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers Hepatology 51 2010 1933 1944
5. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdaydin Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
6. R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Martinot-Peignoux Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
7. V. Rijckborst, B.E. Hansen, Y. Cakaloglu, P. Ferenci, F. Tabak, and M. Akdogan Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels Hepatology 52 2010 454 461
8. M.J. Sonneveld, V. Rijckborst, C.A. Boucher, B.E. Hansen, and H.L. Janssen Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline Hepatology 52 2010 1251 1257
9. Y.F. Liaw The clinical utility of HBsAg quantitation in chronic hepatitis B patients: a review Hepatology 54 2011 E1 E9
10. Kim SS, Lee D, Lee MH, Cheong JY, Cho SW. Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatol Res, in press, http://dx.doi.org/10.1111/j.1872-034X.2012. 01065.x.
11. J.M. Lee, S.H. Ahn, H.S. Kim, H. Park, H.Y. Chang, and D.Y. Kim Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir Hepatology 53 2011 1486 1493
12. M.H. Lee, D.M. Lee, S.S. Kim, J.Y. Cheong, and S.W. Cho Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B J Med Virol 83 2011 1178 1186
13. S. Maylin, A. Boyd, F. Lavocat, J. Gozlan, C. Lascoux-Combe, and P. Miailhes Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients AIDS 26 2012 939 949
14. J.W. Shin, S.W. Jung, B.R. Park, C.J. Kim, J.B. Eum, and B.G. Kim Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels J Viral Hepat 19 2012 724 731
15. K. Wursthorn, J. Jaroszewicz, B.J. Zacher, M. Darnedde, R. Raupach, and I. Mederacke Correlation between the Elecsys HBsAg II assay and the architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum J Clin Virol 50 2011 292 296
16. M.J. Sonneveld, V. Rijckborst, C.A. Boucher, L. Zwang, M.F. Beersma, and B.E. Hansen A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B J Clin Virol 51 2011 175 178
17. T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, and F.J. Carrilho Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
18. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. De Man, and Z. Krastev Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
19. G. Woo, G. Tomlinson, Y. Nishikawa, M. Kowgier, M. Sherman, and D.K. Wong Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
20. E.K. Manesis, E.S. Hadziyannis, O.P. Angelopoulou, and S.J. Hadziyannis Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 2007 73 82 (Pubitemid 46340428)
21. J.G. Reijnders, V. Rijckborst, M.J. Sonneveld, S.M. Scherbeijn, C.A. Boucher, and B.E. Hansen Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir J Hepatol 54 2010 449 454
22. K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
23. J. Jaroszewicz, H. Ho, A. Markova, K. Deterding, K. Wursthorn, and S. Schulz Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues Antivir Ther 16 2011 915 924
24. R. Zoutendijk, B.E. Hansen, A.J. van Vuuren, C.A. Boucher, and H.L. Janssen Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss J Infect Dis 204 2011 415 418
25. V. Thibault, H. Stitou, N. Desire, M.A. Valantin, R. Tubiana, and C. Katlama Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients Antivir Ther 16 2011 199 205
26. S. Chevaliez, M. Bouvier-Alias, S. Laperche, C. Hezode, and J.M. Pawlotsky Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification J Clin Microbiol 48 2010 3641 3647
27. C. Pallier, C. Rodriguez, R. Brillet, P. Nordmann, C. Hezode, and J.M. Pawlotsky Complex dynamics of hepatitis B virus resistance to adefovir Hepatology 49 2009 50 59
28. C. Pichoud, B. Seigneres, Z. Wang, C. Trepo, and F. Zoulim Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance Hepatology 29 1999 230 237 (Pubitemid 29024007)
29. L. Stuyver, S. De Gendt, C. Van Geyt, F. Zoulim, M. Fried, and R.F. Schinazi A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness J Gen Virol 81 2000 67 74 (Pubitemid 30047907)
30. E. Gane, E.J. Heathcote, P. Marcellin, G. Dusheiko, I. Jacobson, and R. de Man HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment J Hepatol 52 2010 S388
31. M.R. Brunetto A new role for an old marker, HBsAg J Hepatol 52 2010 475 477
32. H.L. Chan, V.W. Wong, G.L. Wong, C.H. Tse, H.Y. Chan, and J.J. Sung A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B Hepatology 52 2010 1232 1241
33. H. Ma, R.F. Yang, and L. Wei Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients J Gastroenterol Hepatol 25 2010 1498 1506
34. P. Marcellin, T. Piratvisuth, M.R. Brunetto, F. Bonino, P. Farci, and C. Yurdaydin On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alpha-2a Hepatol Int 4 2010 151
35. T. Piratvisuth, G.K. Lau, P. Marcellin, M.R. Brunetto, H.P. Kapprell, and M. Popescu On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months pots-treatment in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alpha-2a Hepatol Int 4 2010 152
36. A. Gramenzi, E. Loggi, L. Micco, C. Cursaro, S. Fiorino, and S. Galli Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients J Viral Hepat 18 2011 e468 e474